10-K Filing

BEONE MEDICINES LTD. CIK: 1651308 FY 2023

Filing Information

Form Type	10-K
Accession Number	`0001651308-24-000014`
Period End Date	20231231
Filing Date	20240226
Fiscal Year	2023
Fiscal Period	FY
XBRL Instance	bgne-20231231_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 86 Income Statement 60 Cash Flow Statement 131 Stockholders Equity 10 Comprehensive Income 15

Balance Sheet 86 line items

Line Item	Tag	Value	Unit	Period
Ordinary shares, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Ordinary shares, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Ordinary shares, shares authorized (in shares)	`CommonStockSharesAuthorized`	9.50B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$4.38B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.87B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.17B	USD	Point-in-time
Ordinary shares, shares authorized (in shares)	`CommonStockSharesAuthorized`	9.50B	shares	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$328.00K	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$196.00K	USD	Point-in-time
Ordinary shares, shares issued (in shares)	`CommonStockSharesIssued`	1.36B	shares	Point-in-time
Ordinary shares, shares issued (in shares)	`CommonStockSharesIssued`	1.36B	shares	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$11.47M	USD	Point-in-time
Ordinary shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	1.36B	shares	Point-in-time
Ordinary shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	1.36B	shares	Point-in-time
Short-term investments	`DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent`	$665.25M	USD	Point-in-time
Short-term investments	`DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent`	$2.60M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$173.17M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$358.03M	USD	Point-in-time
Inventories, net	`InventoryNet`	$416.12M	USD	Point-in-time
Inventories, net	`InventoryNet`	$282.35M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$243.39M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$216.55M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$5.21B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$4.20B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$1.32B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$845.95M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$95.21M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$109.96M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$40.62M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$57.14M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$175.69M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$125.36M	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$1.17B	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$1.60B	USD	Point-in-time
Total assets	`Assets`	$6.38B	USD	Point-in-time
Total assets	`Assets`	$5.81B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$294.78M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$315.11M	USD	Point-in-time
Accrued expenses and other payables	`AccruedLiabilitiesCurrent`	$467.35M	USD	Point-in-time
Accrued expenses and other payables	`AccruedLiabilitiesCurrent`	$693.73M	USD	Point-in-time
Deferred revenue, current portion	`ContractWithCustomerLiabilityCurrent`	$213.86M	USD	Point-in-time
Deferred revenue, current portion	`ContractWithCustomerLiabilityCurrent`	-	USD	Point-in-time
Tax payable	`TaxesPayableCurrent`	$22.95M	USD	Point-in-time
Tax payable	`TaxesPayableCurrent`	$25.19M	USD	Point-in-time
Operating lease liabilities, current portion	`OperatingLeaseLiabilityCurrent`	$24.04M	USD	Point-in-time
Operating lease liabilities, current portion	`OperatingLeaseLiabilityCurrent`	$21.95M	USD	Point-in-time
Research and development cost share liability, current portion	`ResearchAndDevelopmentCostShareLiabilityCurrentPortion`	$114.33M	USD	Point-in-time
Research and development cost share liability, current portion	`ResearchAndDevelopmentCostShareLiabilityCurrentPortion`	$68.00M	USD	Point-in-time
Short-term debt	`LongTermDebtCurrent`	4.89B	CNY	Point-in-time
Short-term debt	`LongTermDebtCurrent`	$688.37M	USD	Point-in-time
Short-term debt	`LongTermDebtCurrent`	2.27B	CNY	Point-in-time
Short-term debt	`LongTermDebtCurrent`	$328.97M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.81B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.47B	USD	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	$197.62M	USD	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	1.44B	CNY	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	1.40B	CNY	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	$209.15M	USD	Point-in-time
Deferred revenue, non-current portion	`ContractWithCustomerLiabilityNoncurrent`	$300.00K	USD	Point-in-time
Deferred revenue, non-current portion	`ContractWithCustomerLiabilityNoncurrent`	$42.03M	USD	Point-in-time
Operating lease liabilities, non-current portion	`OperatingLeaseLiabilityNoncurrent`	$22.25M	USD	Point-in-time
Operating lease liabilities, non-current portion	`OperatingLeaseLiabilityNoncurrent`	$34.52M	USD	Point-in-time
Deferred tax liabilities	`DeferredIncomeTaxLiabilitiesNet`	$16.49M	USD	Point-in-time
Deferred tax liabilities	`DeferredIncomeTaxLiabilitiesNet`	$16.00M	USD	Point-in-time
Research and development cost share liability, non-current portion	`ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion`	$170.66M	USD	Point-in-time
Research and development cost share liability, non-current portion	`ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion`	$179.62M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$50.51M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$46.09M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$457.83M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$527.41M	USD	Point-in-time
Total liabilities	`Liabilities`	$2.27B	USD	Point-in-time
Total liabilities	`Liabilities`	$2.00B	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,359,513,224 and 1,356,140,180 shares issued and outstanding as of December 31, 2023 and 2022, respectively	`CommonStockValue`	$135.00K	USD	Point-in-time
Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,359,513,224 and 1,356,140,180 shares issued and outstanding as of December 31, 2023 and 2022, respectively	`CommonStockValue`	$135.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$11.60B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$11.54B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-77.42M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-99.45M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-7.96B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-7.08B	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$4.38B	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$3.54B	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$5.81B	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$6.38B	USD	Point-in-time

Income Statement 60 line items

Line Item	Tag	Value	Unit	Period
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.18B	USD	Annual
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.42B	USD	Annual
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$2.46B	USD	Annual
Gross profit	`GrossProfit`	$1.13B	USD	Annual
Gross profit	`GrossProfit`	$1.01B	USD	Annual
Gross profit	`GrossProfit`	$2.08B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.78B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.46B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.64B	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$1.28B	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$1.50B	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$990.12M	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssetsIncludedInOperatingExpenses`	$750.00K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssetsIncludedInOperatingExpenses`	$3.50M	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssetsIncludedInOperatingExpenses`	$751.00K	USD	Annual
Total operating expenses	`CostsAndExpenses`	$2.92B	USD	Annual
Total operating expenses	`CostsAndExpenses`	$3.29B	USD	Annual
Total operating expenses	`CostsAndExpenses`	$2.45B	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-1.44B	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-1.21B	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-1.79B	USD	Annual
Interest income (expense), net	`InterestIncomeExpenseNet`	$74.01M	USD	Annual
Interest income (expense), net	`InterestIncomeExpenseNet`	$-15.76M	USD	Annual
Interest income (expense), net	`InterestIncomeExpenseNet`	$52.48M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$15.90M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-223.85M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$307.89M	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-825.84M	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-1.44B	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-1.96B	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$42.78M	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$19.23M	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$55.87M	USD	Annual
Net loss	`NetIncomeLoss`	$-881.71M	USD	Annual
Net loss	`NetIncomeLoss`	$-1.46B	USD	Annual
Net loss	`NetIncomeLoss`	$-2.00B	USD	Annual
Net loss per share attributable to BeiGene, Ltd., basic (in dollars per share)	`EarningsPerShareBasic`	$-0.65	USD	Annual
Net loss per share attributable to BeiGene, Ltd., basic (in dollars per share)	`EarningsPerShareBasic`	$-1.21	USD	Annual
Net loss per share attributable to BeiGene, Ltd., basic (in dollars per share)	`EarningsPerShareBasic`	$-1.49	USD	Annual
Net loss per share attributable to BeiGene, Ltd., diluted (in dollars per share)	`EarningsPerShareDiluted`	$-1.49	USD	Annual
Net loss per share attributable to BeiGene, Ltd., diluted (in dollars per share)	`EarningsPerShareDiluted`	$-0.65	USD	Annual
Net loss per share attributable to BeiGene, Ltd., diluted (in dollars per share)	`EarningsPerShareDiluted`	$-1.21	USD	Annual
Weighted-average shares outstanding, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	1.21B	shares	Annual
Weighted-average shares outstanding, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	1.34B	shares	Annual
Weighted-average shares outstanding, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	1.36B	shares	Annual
Weighted-average shares outstanding, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.36B	shares	Annual
Weighted-average shares outstanding, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.34B	shares	Annual
Weighted-average shares outstanding, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.21B	shares	Annual
Net loss per American Depositary Share (ADS), basic (in dollars per share)	`EarningsPerAmericanDepositoryShareBasic`	$-8.45	USD	Annual
Net loss per American Depositary Share (ADS), basic (in dollars per share)	`EarningsPerAmericanDepositoryShareBasic`	$-15.71	USD	Annual
Net loss per American Depositary Share (ADS), basic (in dollars per share)	`EarningsPerAmericanDepositoryShareBasic`	$-19.43	USD	Annual
Net loss per American Depositary Share (ADS), diluted (in dollars per share)	`EarningsPerAmericanDepositoryShareDiluted`	$-19.43	USD	Annual
Net loss per American Depositary Share (ADS), diluted (in dollars per share)	`EarningsPerAmericanDepositoryShareDiluted`	$-8.45	USD	Annual
Net loss per American Depositary Share (ADS), diluted (in dollars per share)	`EarningsPerAmericanDepositoryShareDiluted`	$-15.71	USD	Annual
Weighted-average ADSs outstanding, basic (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic`	104.39M	shares	Annual
Weighted-average ADSs outstanding, basic (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic`	92.79M	shares	Annual
Weighted-average ADSs outstanding, basic (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic`	103.13M	shares	Annual
Weighted-average ADSs outstanding, diluted (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted`	103.13M	shares	Annual
Weighted-average ADSs outstanding, diluted (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted`	92.79M	shares	Annual
Weighted-average ADSs outstanding, diluted (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted`	104.39M	shares	Annual

Cash Flow Statement 131 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-881.71M	USD	Annual
Net loss	`ProfitLoss`	$-2.00B	USD	Annual
Net loss	`ProfitLoss`	$-1.46B	USD	Annual
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$66.28M	USD	Annual
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$46.46M	USD	Annual
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$87.67M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$303.16M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$240.71M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$367.62M	USD	Annual
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$83.50M	USD	Annual
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$46.80M	USD	Annual
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$68.67M	USD	Annual
Amortization of research and development cost share liability	`AmortizationOfResearchAndDevelopmentFinancingLiability`	$-112.49M	USD	Annual
Amortization of research and development cost share liability	`AmortizationOfResearchAndDevelopmentFinancingLiability`	$-55.29M	USD	Annual
Amortization of research and development cost share liability	`AmortizationOfResearchAndDevelopmentFinancingLiability`	$-96.40M	USD	Annual
Unrealized losses (gains) on long-term investments	`IncomeLossFromEquityMethodInvestments`	$-16.22M	USD	Annual
Unrealized losses (gains) on long-term investments	`IncomeLossFromEquityMethodInvestments`	$-22.00M	USD	Annual
Unrealized losses (gains) on long-term investments	`IncomeLossFromEquityMethodInvestments`	$7.63M	USD	Annual
Deferred income tax expense	`DeferredIncomeTaxesAndTaxCredits`	$3.38M	USD	Annual
Deferred income tax expense	`DeferredIncomeTaxesAndTaxCredits`	$2.06M	USD	Annual
Deferred income tax expense	`DeferredIncomeTaxesAndTaxCredits`	$689.00K	USD	Annual
Gain on BMS termination settlement	`GainLossRelatedToLitigationSettlement`	-	USD	Annual
Gain on BMS termination settlement	`GainLossRelatedToLitigationSettlement`	$362.92M	USD	Annual
Gain on BMS termination settlement	`GainLossRelatedToLitigationSettlement`	-	USD	Annual
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$-6.00M	USD	Annual
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$23.51M	USD	Annual
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$9.05M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$423.02M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-304.11M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$188.31M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$153.33M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$56.69M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$140.95M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$3.28M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$107.13M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-12.12M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$20.01M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-4.35M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$21.48M	USD	Annual
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$180.11M	USD	Annual
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$45.63M	USD	Annual
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$140.04M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-151.82M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$407.70M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-255.59M	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$-1.21M	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$587.00K	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$-2.62M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.16B	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.50B	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.30B	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$325.43M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$561.90M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$262.94M	USD	Annual
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$2.08M	USD	Annual
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$1.49M	USD	Annual
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$2.15B	USD	Annual
Proceeds from sale or maturity of short-term investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$3.15B	USD	Annual
Proceeds from sale or maturity of short-term investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$673.24M	USD	Annual
Proceeds from sale or maturity of short-term investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$1.56B	USD	Annual
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$15.00M	USD	Annual
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$143.66M	USD	Annual
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$8.50M	USD	Annual
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	$19.36M	USD	Annual
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	-	USD	Annual
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	$43.41M	USD	Annual
Purchase of long-term investments	`PaymentsToAcquireLongtermInvestments`	$15.91M	USD	Annual
Purchase of long-term investments	`PaymentsToAcquireLongtermInvestments`	$43.50M	USD	Annual
Purchase of long-term investments	`PaymentsToAcquireLongtermInvestments`	$14.90M	USD	Annual
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$640.66M	USD	Annual
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.08B	USD	Annual
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$60.00M	USD	Annual
Proceeds from public offering, net of cost	`ProceedsFromIssuanceInitialPublicOffering`	-	USD	Annual
Proceeds from public offering, net of cost	`ProceedsFromIssuanceInitialPublicOffering`	-	USD	Annual
Proceeds from public offering, net of cost	`ProceedsFromIssuanceInitialPublicOffering`	$3.39B	USD	Annual
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStock`	$50.00M	USD	Annual
Proceeds from long-term loan	`ProceedsFromLongTermLinesOfCredit`	$37.37M	USD	Annual
Proceeds from long-term loan	`ProceedsFromLongTermLinesOfCredit`	$16.84M	USD	Annual
Proceeds from long-term loan	`ProceedsFromLongTermLinesOfCredit`	$22.50M	USD	Annual
Repayment of long-term loan	`RepaymentsOfLongTermDebt`	$13.69M	USD	Annual
Repayment of long-term loan	`RepaymentsOfLongTermDebt`	-	USD	Annual
Repayment of long-term loan	`RepaymentsOfLongTermDebt`	-	USD	Annual
Proceeds from short-term loans	`ProceedsFromShortTermDebt`	$661.53M	USD	Annual
Proceeds from short-term loans	`ProceedsFromShortTermDebt`	$313.77M	USD	Annual
Proceeds from short-term loans	`ProceedsFromShortTermDebt`	$406.45M	USD	Annual
Repayment of short-term loans	`RepaymentsOfShortTermDebt`	$417.08M	USD	Annual
Repayment of short-term loans	`RepaymentsOfShortTermDebt`	$309.58M	USD	Annual
Repayment of short-term loans	`RepaymentsOfShortTermDebt`	$321.75M	USD	Annual
Proceeds from option exercises and employee share purchase plan	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$46.96M	USD	Annual
Proceeds from option exercises and employee share purchase plan	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$55.71M	USD	Annual
Proceeds from option exercises and employee share purchase plan	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$92.76M	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$416.48M	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$3.64B	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-18.97M	USD	Annual
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-69.38M	USD	Annual
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$14.04M	USD	Annual
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-8.08M	USD	Annual
Net (decrease) increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-689.05M	USD	Annual
Net (decrease) increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-507.85M	USD	Annual
Net (decrease) increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$2.99B	USD	Annual
Cash, cash equivalents, and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$3.88B	USD	Point-in-time
Cash, cash equivalents, and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.39B	USD	Point-in-time
Cash, cash equivalents, and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$4.38B	USD	Point-in-time
Cash, cash equivalents, and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$3.19B	USD	Point-in-time
Cash, cash equivalents, and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$3.88B	USD	Point-in-time
Cash, cash equivalents, and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.39B	USD	Point-in-time
Cash, cash equivalents, and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$4.38B	USD	Point-in-time
Cash, cash equivalents, and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$3.19B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$4.38B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.87B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.17B	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$328.00K	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$196.00K	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$11.47M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$2.71M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$5.28M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$6.88M	USD	Point-in-time
Income taxes paid	`IncomeTaxesPaidNet`	$15.70M	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	$29.50M	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	$56.00M	USD	Annual
Interest paid	`InterestPaidNet`	$29.97M	USD	Annual
Interest paid	`InterestPaidNet`	$19.75M	USD	Annual
Interest paid	`InterestPaidNet`	$25.17M	USD	Annual
Accruals for capital expenditures	`CapitalExpendituresIncurredButNotYetPaid`	$95.35M	USD	Annual
Accruals for capital expenditures	`CapitalExpendituresIncurredButNotYetPaid`	$91.80M	USD	Annual
Accruals for capital expenditures	`CapitalExpendituresIncurredButNotYetPaid`	$53.20M	USD	Annual
Purchase of in-process research and development included in accounts payable	`AcquiredInProcessResearchAndDevelopmentButNotYetPaid`	$31.80M	USD	Annual
Purchase of in-process research and development included in accounts payable	`AcquiredInProcessResearchAndDevelopmentButNotYetPaid`	-	USD	Annual
Purchase of in-process research and development included in accounts payable	`AcquiredInProcessResearchAndDevelopmentButNotYetPaid`	$75.00M	USD	Annual

Stockholders Equity 10 line items

Line Item	Tag	Value	Unit	Period
Balance at the beginning of period (in shares)	`CommonStockSharesOutstanding`	1.36B	shares	Point-in-time
Balance at the beginning of period (in shares)	`CommonStockSharesOutstanding`	1.36B	shares	Point-in-time
Use of shares reserved for share option exercises (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	6.97M	shares	Annual
Use of shares reserved for share option exercises (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	5.90M	shares	Annual
Use of shares reserved for share option exercises (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	17.23M	shares	Annual
Net loss	`ProfitLoss`	$-881.71M	USD	Annual
Net loss	`ProfitLoss`	$-2.00B	USD	Annual
Net loss	`ProfitLoss`	$-1.46B	USD	Annual
Balance at the ending of period (in shares)	`CommonStockSharesOutstanding`	1.36B	shares	Point-in-time
Balance at the ending of period (in shares)	`CommonStockSharesOutstanding`	1.36B	shares	Point-in-time

Comprehensive Income 15 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-881.71M	USD	Annual
Net loss	`ProfitLoss`	$-2.00B	USD	Annual
Net loss	`ProfitLoss`	$-1.46B	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$13.71M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-90.42M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-25.46M	USD	Annual
Pension liability adjustments, net	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$5.61M	USD	Annual
Pension liability adjustments, net	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$-1.86M	USD	Annual
Pension liability adjustments, net	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$-365.00K	USD	Annual
Unrealized holding loss, net	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-4.57M	USD	Annual
Unrealized holding loss, net	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-5.31M	USD	Annual
Unrealized holding loss, net	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$9.05M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-903.74M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-2.10B	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-1.45B	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.